Intravitreal therapy with ranibizumab vs aflibercept vs bevacizumab for macular oedema due to central retinal vein occlusion : a within trial cost-utility analysis

Flight, L. orcid.org/0000-0002-9569-8290, Alshreef, A. orcid.org/0000-0003-2737-1365, Hykin, P.G. et al. (5 more authors) (2019) Intravitreal therapy with ranibizumab vs aflibercept vs bevacizumab for macular oedema due to central retinal vein occlusion : a within trial cost-utility analysis. In: Value in Health. ISPOR Europe 2019, 02-06 Nov 2019, Copenhagen, Denmark. Elsevier , S664-S664.

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2019 Elsevier. This is an author produced version of a paper subsequently published in Value in Health. Uploaded in accordance with the publisher's self-archiving policy. Article available under the terms of the CC-BY-NC-ND licence (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Dates:
  • Published (online): 17 December 2019
  • Published: November 2019
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield) > Sheffield Centre for Health and Related Research
Funding Information:
FunderGrant number
National Institute for Health ResearchN/A
Depositing User: Symplectic Sheffield
Date Deposited: 08 Jan 2020 10:02
Last Modified: 08 Jan 2020 10:02
Published Version: https://www.ispor.org/heor-resources/presentations...
Status: Published
Publisher: Elsevier
Refereed: Yes
Identification Number: https://doi.org/10.1016/j.jval.2019.09.1396
Related URLs:

Download

Accepted Version


Embargoed until: 17 December 2020

Filename: Flight et al 2019 Intravitreal therapy, ISPOR abstract.pdf

Licence: CC-BY-NC-ND 4.0

Request a copy

Share / Export

Statistics